Recent Updates
Recently added Catalysts

SciSparc Ltd.

SPRCFDA catalysts, PDUFA dates & pipeline intelligence
$0.3
▲ +0.03 · +11.07%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full SPRC financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $0.2352W HIGH $29.88
Volume
79.32 M
Value Traded
-
Short % Float
3.43%
Days to Cover
1.0
-15.56%Week
-77.44%1 Month
-95.47%3 Month
-92.86%6 Month
-99.98%5 Year
-99.98%All Time

Cash Data

Unlock SPRC cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
739.03 K
EPS (TTM)
-231.49
P/E Ratio
-
Ent. Value
-889.25 K
Total Shares
2.46 M
Float Shares
2.02 M
Insiders
1.85%
Institutions
1.45%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every SPRC catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

SPRC Catalyst Timeline

Dated clinical, regulatory and corporate events for SciSparc Ltd.

Catalyst Timeline

Dated clinical, regulatory & corporate events for SciSparc Ltd.

343Total events
4Upcoming
86Tier-1 (high impact)
2017 to 2026Coverage

Upcoming catalysts 2

TBD
T1Acquisition
Subscribe to view catalyst details
TBD
T2Orphan Drug Designation
Subscribe to view catalyst details
SCI-110

Event history 50

●Management ChangeCorporate
Prof. Jacob Nagel appointed to Scientific Advisory Board for AI and Cybersecurity
▲Manufacturing MilestoneSCI-110CMC / Inspection
NeuroThera completes manufacturing and European QP batch release of SCI-110 clinical trial material
Tourette Syndromesource ↗
▲Trial InitiationSCI-110Trial
All three Phase IIb sites complete site initiation activities for SCI-110 in Tourette Syndrome
Tourette Syndromesource ↗
◆Timing GuidancePresentation
SciSparc to shift strategic focus toward Agentic AI-powered technologies, including cybersecurity and finance
●Timing GuidancePresentation
SciSparc announces strategic shift toward Agentic AI-powered technologies including cybersecurity and finance
▲Platform ValidationPreclinical
CliniQuantum reports ~16.8-fold GPU acceleration of quantum-simulation platform on real-world clinical gene-expression data
●Composition Patent FiledIP / Competition
Three U.S. patent applications published covering LSD, ketamine and ibogaine combinations with PEA
depression, PTSD, pain, substance use disorderssource ↗
▲Partnership / LicenseCorporate
NeuroThera engages RK Strategies for government and public affairs consulting
▲Trial InitiationSCI-110Trial
Initiation of Phase IIb program for SCI-110 in Tourette Syndrome
Tourette Syndromesource ↗
▲Enrollment UpdateSCI-210Trial
Enrollment reaches 26 of planned 60 children in SCI-210 autism trial
autism spectrum disordersource ↗
Unlock the full SPRC catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How SPRC actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all SPRC historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 86%
Micro Cap
(rank 622 of 723)
Percentile Rank
Showing 1 of 2 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
SCI-110 Small MoleculesNCT05126888Tourette SyndromePhase 2 NOT YET_RECRUITING 164Feb 1, 2028
Unlock the SPRC pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every SPRC program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
SCI-110 Tourette SyndromePhase 2b2026-08-05average tic reduction of 21% across the entire participants sampleRead MoreSciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette SyndromeRead More
Scroll for more · summaries link to the source press release
Unlock every SPRC trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock SPRC insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Shrem ItschakDirectorSell -462 10,596 held$10.00 06/01/2026
Unlock the full SPRC insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in SPRC for Q3 2026.
Unlock every fund holding SPRC
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in SPRC
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see SPRC ownership
Insider and institutional ownership, quarter by quarter.

SPRC Short Interest

Shares sold short, counted twice a month.

3.43%
Short % of Float
of tradable shares sold short
69.4K
Shares Sold Short
+471.9% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
4.4M
Avg Daily Volume
the average used for days to cover
Unlock SPRC short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock SPRC option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live SPRC option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock SPRC options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How SPRC ranks across every disease it competes in

Competitive Position is a premium feature
See how SPRC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

SPRC News

SPRC
Nov 16, 2026
SPRCGeneral
▼ -6.3%on this news

SciSparc: Former National Security Advisor to Prime Minister Benjamin Netanyahu Renowned AI Prof. Jacob Nagel Joins the Company’s SAB

SciSparc Ltd. appointed Prof. Jacob Nagel to its Scientific Advisory Board, enhancing its focus on Agentic AI. Nagel, a former national security advisor, brings extensive experience in AI and cybersecurity. This move supports SciSparc's strategic entry into the Agentic AI sector, following the addition of another AI expert, Prof. Carmel Domshlak.

Read more →
SPRC
Oct 22, 2026
SPRCPhases
▼ -10.4%on this news· ran to -37% by day 3

SciSparc: Subsidiary NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome

SciSparc's subsidiary, NeuroThera Labs, reported progress in its FDA-approved Phase IIb trial for SCI-110, aimed at treating Tourette Syndrome. The company has completed product manufacturing and received batch release certification, enabling clinical trial material shipment. Patient enrollment is set to begin soon at three clinical sites across the USA, Germany, and Israel.

Read more →
SPRC
Oct 19, 2026
SPRCGeneral
▼ -17.6%on this news· ran to -29% by day 3shared move

SciSparc Shifts Focus to Agentic AI, Targeting Cybersecurity and Finance Applications

SciSparc Ltd. is shifting its strategic focus towards Agentic AI technologies, particularly in cybersecurity and finance. This decision follows previous announcements and the establishment of a Scientific Advisory Board. The company aims to explore new opportunities within the Agentic AI ecosystem, although there are no guarantees of success or revenue generation from these efforts.

Read more →
SPRC
Oct 15, 2026
SPRCGeneral
▼ -44.9%on this news· ran to -63% by day 3shared move

SciSparc Announces Transformation into Agentic AI-Powered Technologies, Including Cybersecurity and Finance Technologies

SciSparc Ltd. is transitioning its focus to Agentic AI-powered technologies, particularly in cybersecurity and finance. This decision follows previous announcements regarding the establishment of a Scientific Advisory Board. The company aims to explore opportunities within the Agentic AI ecosystem, although there are no guarantees of successful outcomes from these initiatives.

Read more →
SPRC
Oct 7, 2026
SPRCGeneral
▲ +7.2%on this news

SciSparc: Subsidiary NeuroThera Labs’ CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company’s Quantum Architecture

SciSparc's subsidiary, NeuroThera Labs, reported a successful quantum-enabled analysis of gene combinations using real-world clinical data. Their CliniQuantum platform achieved a 16.8-fold computational acceleration compared to traditional methods. The analysis identified over 22 million correlated gene triplets, showcasing the potential of quantum computing in biomedical research, although clinical validity remains unverified.

Read more →
SPRC
Sep 23, 2026
SPRCGeneral
▲ +9.6%on this news

SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations

SciSparc Ltd. announced that its subsidiary NeuroThera has expanded its U.S. patent portfolio through collaboration with Clearmind Medicine. The new patent applications cover combinations of PEA technology with LSD, ketamine, and ibogaine, targeting mental health disorders such as depression and PTSD. This collaboration aims to develop safer and more effective treatments for various neuropsychiatric conditions.

Read more →
SPRC
Sep 2, 2026
SPRCFDA Updates

SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies

SciSparc's subsidiary, NeuroThera Labs, is seeking FDA Orphan Drug Designation for SCI-110, a treatment for adult Tourette Syndrome. The engagement of RK Strategies aims to boost visibility and support regulatory pathways. SCI-110 has shown promising early clinical results, achieving a 21% tic reduction in Phase IIa trials, and is now advancing into Phase IIb trials across multiple academic centers.

Read more →
SPRC
Aug 31, 2026
SPRCPhases
▼ -14.5%on this newsshared move

SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial

SciSparc Ltd. announced that its subsidiary, NeuroThera Labs, has made significant progress in enrolling participants for the SCI-210 clinical trial aimed at treating autism spectrum disorder. With 26 out of 60 children enrolled, the trial evaluates the safety and efficacy of SCI-210, a combination of CBD and CannAmide™, over a 20-week period. The study is designed to assess whether this dual-compound treatment is more effective than CBD alone.

Read more →
SPRC
Aug 26, 2026
SPRCGeneral

SciSparc Advances Agentic AI Strategy with Addition of Internationally Recognized AI Expert Prof. Carmel Domshlak to Scientific Advisory Board

SciSparc Ltd. has appointed Prof. Carmel Domshlak, a prominent AI researcher, to its Scientific Advisory Board, effective September 1, 2026. This move aims to bolster the company's capabilities in the Agentic AI market. Prof. Domshlak's extensive experience and accolades in AI research will support SciSparc's strategic focus on this rapidly evolving field.

Read more →
SPRC
Aug 24, 2026
SPRCFDA Updates

SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation

SciSparc Ltd. announced the publication of a patent application for a combination of MDMA and N-acylethanolamines aimed at treating PTSD, anxiety, and eating disorders. This development is part of a collaboration with Clearmind Medicine, which has resulted in a significant intellectual property portfolio. The FDA's recent guidance on psychedelic drugs further supports the regulatory framework for this collaboration.

Read more →
SPRC
Aug 18, 2026
SPRCGeneral

SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc’s Stake Valued at Approximately C$30 Million

SciSparc Ltd. has announced that its subsidiary, NeuroThera Labs, completed a C$5.4 million financing round, with SciSparc contributing C$2.7 million. Following this investment, SciSparc holds approximately 44.6% of NeuroThera's shares, valued at C$30 million. The funds will be used for general working capital and corporate expenses.

Read more →
SPRC
Aug 12, 2026
SPRCGeneral

SciSparc’s Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination

SciSparc Ltd.'s subsidiary, NeuroThera Labs, has been granted a Japanese patent for its innovative pharmacological combination aimed at enhancing the efficacy of 4-aminophenol derivatives. This patent is a significant milestone for NeuroThera as it expands its intellectual property and aims to modernize treatments for pain and fever. The combination therapy is designed to potentially lower dosing and mitigate side effects.

Read more →
SPRC
Aug 5, 2026
SPRCPhases

SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome

SciSparc Ltd. announced the launch of a Phase IIb clinical trial for SCI-110, a cannabinoid-based treatment for Tourette Syndrome, at Yale Child Study Center. The trial aims to evaluate the efficacy and safety of SCI-110, building on positive results from a previous Phase IIa study. The study is also being conducted at sites in Germany and Israel, addressing a significant unmet medical need.

Read more →
SPRC
Jul 31, 2026
SPRCGeneral
▼ -18.2%on this newsshared move

SciSparc: Subsidiary NeuroThera Labs' Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics

SciSparc Ltd. announced a significant achievement by its subsidiary, NeuroThera Labs, in developing a hybrid quantum-classical workflow for clinical data analytics. This platform can process real-world clinical data and generate interpretable insights, enhancing the analysis of complex biomedical datasets. Future plans include optimizing algorithms and expanding dataset capabilities.

Read more →
SPRC
Jul 29, 2026
SPRCGeneral
▲ +70.5%on this newsshared move

SciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company

SciSparc Ltd. announced that its subsidiary, NeuroThera Labs, has validated a quantum sampling workflow for clinical data analysis. This platform, developed in collaboration with an S&P 500 company, aims to enhance the analysis of large-scale clinical datasets. The validation marks a significant step toward advanced quantum-enabled analytical capabilities in healthcare.

Read more →
SPRC
Jul 27, 2026
SPRCGeneral
▼ -6%on this news· ran to +63% by day 3shared move

SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity

SciSparc Ltd. has announced its decision to enter the agentic AI market and establish a Scientific Advisory Board focused on AI and cybersecurity. The company is currently evaluating opportunities and engaging in discussions with several firms in the AI sector. This move reflects SciSparc's strategic growth initiatives while continuing its focus on cannabinoid pharmaceuticals.

Read more →
SPRC
Jul 15, 2026
SPRCPhases
▲ +14.8%on this news· ran to +26% by day 1

SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome

SciSparc Ltd. has announced the initiation of a Phase IIb clinical trial for SCI-110, a cannabinoid-based treatment for Tourette Syndrome, at Hannover Medical School in Germany. This trial follows positive results from a Phase IIa study, which indicated a significant reduction in tic severity. The study aims to evaluate the efficacy, safety, and tolerability of SCI-110 in adults aged 18-65.

Read more →
SPRC
Jun 4, 2026
SPRCGeneral
▲ +22%on this news

SciSparc: Subsidiary NeuroThera Labs Completed Acquisition of CliniQuantum

SciSparc Ltd. announced that its subsidiary, NeuroThera Labs, has completed the acquisition of a 54% interest in CliniQuantum. This acquisition, valued at approximately CAD$9.46 million, aims to leverage CliniQuantum's technology for improving clinical trial outcomes. The deal includes potential earn-out payments based on future milestones, highlighting the strategic focus on central nervous system disorders.

Read more →
SPRC
May 28, 2026
SPRCGeneral
▲ +140.3%on this news

SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum

SciSparc Ltd. announced that its subsidiary, NeuroThera Labs, received conditional regulatory approval from the TSX for acquiring a 54% interest in CliniQuantum. The acquisition involves issuing approximately 56.6 million common shares of NeuroThera to CliniQuantum's shareholders. This strategic move aims to enhance NeuroThera's capabilities in developing novel treatments for central nervous system disorders.

Read more →
SPRC
Mar 16, 2026
SPRCGeneral

SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy

SciSparc Ltd. has announced a collaboration with NeuroThera Labs and Clearmind Medicine, resulting in a patent application for a new therapy targeting major depressive disorder. This innovative treatment combines MEAI and PEA, potentially offering a non-hallucinogenic alternative to traditional antidepressants. The patent filing highlights the promise of this combination in addressing depression, a major global health concern.

Read more →

About SciSparc Ltd.

3 employees scisparc.com
BIOPHARMAWATCH ELITE
Trade the next SPRC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime